Lead extractions in patients with cardiac implantable electronic device infections: Single center experience  by Goya, Masahiko et al.
Journal of Arrhythmia 32 (2016) 308–312Contents lists available at ScienceDirectJournal of Arrhythmiahttp://d
1880-42
(http://c
n Corr
Asano 3
fax: þ8
E-m
1 Pr
Dental Ujournal homepage: www.elsevier.com/locate/joaOriginal ArticleLead extractions in patients with cardiac implantable electronic device
infections: Single center experience
Masahiko Goya, MDa,n,1, Michio Nagashima, MDa, Ken-ichi Hiroshima, MDa,
Kentaro Hayashi, MDa, Yu Makihara, MDa, Masato Fukunaga, MDa, Yoshimori An, MDa,
Masatsugu Ohe, MDa, So-ichiro Yamazato, MDa, Ko-ichiro Sonoda, MDa,
Kennosuke Yamashita, MDa, Kouji Katayama b, Tomoaki Ito b, Harushi Niu b,
Kenji Ando, MDa, Hiroyoshi Yokoi, MDa, Masashi Iwabuchi, MDa
a Department of Cardiology, Kokura Memorial Hospital, Japan
b Department of Medical Engineering, Kokura Memorial Hospital, Japana r t i c l e i n f o
Article history:
Received 10 June 2015
Received in revised form
14 December 2015
Accepted 12 February 2016
Available online 22 March 2016
Keywords:
Lead extraction
Laser
Pacemaker
Deﬁbrillator
Infectionx.doi.org/10.1016/j.joa.2016.02.004
76/& 2016 Japanese Heart Rhythm Society. Pu
reativecommons.org/licenses/by-nc-nd/4.0/).
espondence to: Department of Cardiology,
-2-1, Kokurakita-ku, Kitakyushu 802-8555, J
1 3 5803 0133.
ail address: mgoyamd@yahoo.co.jp (M. Goya).
esent address: Department of Cardiovascular
niversity, Yushima 1-5-45, Bunkyo-ku, Tokyoa b s t r a c t
Background: Lead extraction using laser sheaths is performed mainly for cardiac implantable electronic
device (CIED) infections. However, there are few reports concerning the management of CIED infections
in Japan.
Methods and results: Lead extraction procedures were performed in 183 patients targeting 450 leads
(atrial leads: 170, ventricular: 181, implantable cardioverter-deﬁbrillators (ICDs): 79, and coronary sinus:
20). One hundred twenty patients (65.6%) presented with pocket infections without the presentation of
an endovascular infection. Blood cultures were positive at least once in 63 patients (34.4%). Complete
procedure success was achieved for 437 leads (97.1%) while partial removal occurred in nine, and failure
in four leads. Major complications directly related to the procedure occurred in ﬁve patients (2.7%). Two
of the four patients with a cardiac tamponade required a surgical repair. All patients received intravenous
antibiotics, at least, one week after the procedure. Pocket or systemic infections were successfully con-
trolled in 181 patients (98.9%). Coagulase-negative staphylococci (30.1%) and Staphylococcus aureus
(37.1%) were the most common causes of CIED infections.
Conclusion: The current status of CIED infections in Japan seems to be similar to that previously reported
from foreign countries. The optimal treatment of CIED infections involves the complete explantation of
all hardware, followed by antibiotic therapy.
& 2016 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Roughly 40 years have passed since permanent pacemakers
(PMs) became available in clinical medicine. More recently,
implantable cardioverter-deﬁbrillators (ICDs) and cardiac resyn-
chronization therapy (CRT) have been introduced. The rate of
device implantation is increasing with the aging of the general
population and the indications are expanding [1]. Similar to other
prosthetic materials, infections complicate a small proportion of
patients with these devices. With the increase in deviceblished by Elsevier B.V. This is an
Kokura Memorial Hospital,
apan. Tel.: þ81 3 5803 5231;
Medicine, Tokyo Medical and
113-8519, Japan.implantation, the incidence of device infections has also been
growing at a faster rate. We introduced the excimer laser system in
2009 for the transvenous removal of the implanted leads. How-
ever, there have been few reports [2–4] concerning the manage-
ment of cardiac device infections. The purpose of this study was to
review our single center experience and to clarify the current
status of cardiac implantable electronic device (CIED) infections
in Japan.2. Material and methods
2.1. Study patients
All 183 patients with CIED infections who underwent a device
and transvenous lead removal using an excimer laser system in
Kokura Memorial Hospital from July 2009 through March 2014open access article under the CC BY-NC-ND license
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described criteria [5]. Brieﬂy, a pocket infection was deﬁned as the
presence of local warmth, erythema, swelling, edema, pain, or
discharge from the device pocket, or an erosion or impending
erosion of the device. A bloodstream infection was deﬁned as
occult bacteremia despite appropriate antibiotic therapy. Device-
related endocarditis was deﬁned according to the Duke criteria [6].
Blood cultures were obtained from all patients on the day of
admission; cultures were also obtained from the generator and the
tip of the lead at the time of device removal. All patients gave their
written informed consent. The indications for a lead extraction
were decided based on the Heart Rhythm Society Expert con-
sensus statement [5]. The baseline clinical characteristics, patho-
gens, results of the lead extraction procedures, and follow-up
results were analyzed.Table 1
Summary data of the baseline characteristics of the study patients.
Summary data of the patients
No. of patients 183
Gender Male: 131, female: 52
Male, n (%) 131 (72)
Age (years) 72.2714.3
BMI (kg/m2) 22.173.8
WBC 597071620
Cr (mg/dl) 1.171.4
CRP (mg/dl) 1.172.8
Device type, n (%)2.2. Lead extraction procedure
The procedures were performed in the cardiac catheterization
laboratory or operation room under general or venous anesthesia
according to the patient’s condition. Careful monitoring with sur-
face electrocardiograms, invasive arterial blood pressure mon-
itoring, and transesophageal or intracardiac echocardiography
were performed in all patients. There was cardiac surgical backup
and stand-by percutaneous cardio-pulmonary support.
The lead extraction procedure has been previously described
[7]. Brieﬂy, the lead was prepared by inserting a locking stylet into
the inner coil lumen when possible. Then, a suture was tied onto
the insulation and the locking stylet. Next, the laser sheath was
advanced over the lead. A laser application was performed at
binding sites and the laser sheath was gradually advanced from
one binding site to another until the tip of the lead was reached.
Once abutting the myocardium, a combination of traction and
counter-traction was performed and the lead was freed.
The deﬁnition of the outcome has been previously reported in
the consensus statement [5]. Complete procedural success was
deﬁned as the “removal of all targeted leads and all lead material
from the vascular space, with the absence of any permanently
disabling complications or procedure-related deaths.” Clinical
success was deﬁned as the “removal of all targeted leads and lead
material from the vascular space, or retention of a small portion of
the lead that did not negatively impact the outcome goals of the
procedure.” Failure was deﬁned as the “inability to achieve either
complete procedural or clinical success, or the development of any
permanently disabling complications or procedure-related
deaths.”
Major complications were deﬁned as “any of the outcomes
related to the procedure that were life threatening or resulted in
death, and in addition, any unexpected events that caused a per-
sistent or signiﬁcant disability, or any events that required a sig-
niﬁcant surgical intervention to prevent any of the outcomes listed
above.” Minor complications were deﬁned as “any undesired
events related to the procedure that required a medical inter-
vention or minor procedural intervention to remedy, and did not
persistently or signiﬁcantly limit the patient’s function, nor
threaten their life or cause death”.Pacemaker 136 (74.3)
CRT-P 2 (1.1)
ICD 28 (15.3)
CRT-D 17 (9.3)
BMI: body mass index, WBC: white blood cell, Cr: serum creatinine, CRP: C-reactive
protein, CRT: cardiac resynchronization therapy, P: pacing, ICD: implantable car-
dioverter deﬁbrillator, D: deﬁbrillator2.3. Statistical analysis
The continuous variables are expressed as the mean7SD and
were compared using a Student’s t-test. A Po0.05 was considered
signiﬁcant.3. Results
3.1. Baseline characteristics
Two hundred twenty-two lead extraction procedures were
performed between July 2009 and March 2014. One hundred
eighty-three patients (mean 72.2714.3 years old, 131 males) had
explantations of the devices, leads, or both due to infection com-
plications. The patient characteristics are shown in Table 1. One
hundred twenty patients (65.6%) presented with signs and
symptoms of an infection involving the device pocket without the
presentation of an endovascular infection. Blood cultures were
positive at least once in 63 patients (34.4%). Twenty-six of 63
patients were diagnosed with infectious endocarditis according to
Duke’s criteria [6]. Among this cohort, 136 patients (74.3%) had a
permanent PM, 45 (24.6%) had an ICD, and 19 (10.4%) had a
biventricular PM with or without an ICD. The mean duration of the
device implant and device explantation ranged from 2 to 417
months (91.9783.7 months). The mean duration of the implan-
tation or last device replacement and device explantation was
30.5736.2 months. Twenty-seven patients (14.8%) had an early
explantation (o3 months), 45 (24.6%) had a late explantation (4–
12 months), and 111 (60.7%) had a delayed explantation (412
months). Eighty (43.7%) patients underwent a device explantation
due to a late infection more than 24 months after the device-
related procedure.
Eighty-seven patients (47.5%) had a previous surgical inter-
vention without full removal of all the hardware. Twenty-two
patients received a device implantation on the ipsilateral side even
though the infection was active in the PM pocket.
3.2. Lead extraction procedure
One to ﬁve leads were implanted in each patient, and a total of
450 leads were extracted. Twenty-ﬁve leads were extracted by
manual traction; the remaining leads were extracted using an
excimer laser sheath. The summary data of the extracted leads are
shown in Table 2. Among the 450 leads extracted, the positions of
the leads were the right atrium (n¼170, 37.8%), coronary sinus
(n¼20, 4.4%), and right ventricle (n¼260, 57.8%), and included 79
ICD leads. The mean implant duration was 88.5777.6 months in
total, with 92.3776.4 months in the right atrium, 34.9727.6
months in the coronary sinus, and 102.5790.1 months in the right
ventricle; 62.4 735.5 were ICD leads Table 3.
Complete procedural success was achieved with 437 leads
(97.1%), while partial removal in nine (2.0%), and failure with four
Table 2
Summary data of 450 extracted leads.
Number Implant duration (Mo)
No. of extracted leads 450 88.5777.6
Atrial leads 170 92.3776.4
Active ﬁxation atrial lead 53
Passive ﬁxation atrial lead 113
Others 4
Ventricular leads (except ICD) 181 102.5790.1
Active ﬁxation ventricular lead 46
Passive ﬁxation ventricular lead 106
Others 29
Coronary sinus lead 20 34.9727.6
ICD lead 79 62.4735.5
Dual coil active ﬁxation ICD lead 63
Dual coil passive ﬁxation ICD lead 10
Single coil active ﬁxation ICD lead 4
Single coil passive ﬁxation ICD lead 2
Mo: months.
Table 3
Summary data of the pathogens isolated from the study patients.
Organism No. %
Aerobic Gram-positive
Coagulase-negative Staphylococcus aureus 55 30.1
Methicillin-sensitive Staphylococcus aureus 48 26.2
Methicillin-resistant Staphylococcus aureus 20 10.9
Streptococcus agalactiae 1 0.5
Enterococcus faecalis 1 0.5
Corynebacterium 8 4.4
Propionibacterium acnes 3 1.6
Gram-Negative
Pseudomonous aeruginosa 3 1.6
Escherichia coli 2 1.1
Proteus mirabilis 1 0.5
Anaerobes 4 2.2
Fungi
Candida species 2 1.1
Others
Mycobacterium species 2 1.1
Culture Negative 33 18
Fig. 1. Left: A vegetation (2.5 cm) attached to the leads was detected by transeso
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partial removals was 86.1775.9 months and 162.07101.0
months, respectively (po0.01). In all cases of partial removal, only
the tip of the lead remained in the myocardium without any
complications and the desired clinical outcomes could be
achieved. In two patients, open heart surgery was performed
because of a large vegetation (Fig. 1). In those cases, the proximal
portion of the leads was extracted using an excimer laser sheath
from the PM pocket. With another four leads in two patients, the
leads were also removed during open heart surgery due to cardiac
tamponade encountered during the lead extraction procedure.
Major complications directly related to the lead extraction
procedure occurred in ﬁve patients (2.7%, cardiac tamponade in
four, and death within 24 h after the procedure due to
uncontrollable bleeding from the vein in one patient). Two of the
four patients with cardiac tamponades required a surgical repair.
Further, minor adverse events occurred in seven more patients
(3.8%, pneumothorax in two, blood transfusion in four, and pul-
monary embolism in one patient). Four patients (2.2%) died during
the index hospitalization. Two patients died because the systemic
infection could not be controlled even after the removal of all
implanted devices. One patient died during the hospital stay
because of a cerebral infarction not related to the extraction
procedure.
All patients received intravenous antibiotics, at least, one week
after the procedure. Pocket or systemic infections were success-
fully controlled in 181 patients (98.9%).
A re-implantation of the device was performed 26.2712.9 days
after the explantation. Fifteen of 183 patients (8.2%) did not
require further device therapy, and devices were implanted in the
remaining patients. Eight of these patients were transferred to
another hospital for the re-implantation procedure. Two patients
had recurrences of infection within one year after the explantation
of the devices.
3.3. Microbiology
Coagulase-negative staphylococci (CNS, 30.1%, Fig. 2) and Sta-
phylococcus aureus (37.1%) were the most common causes of CIED
infections followed by the Corynebacterium species (eight
patients). Gram-negative bacilli including Pseudomonas aeruginosa
(three patients), Escherichia coli (two patients), and Proteus mir-
abilis were the pathogens in 3.8%. Seven patients had an anaerobic
gram-positive bacillus species and two patients had a fungal
(Candida albicans) infection. Thirty-three (18%) patients had loca-
lized inﬂammatory signs in the generator pocket or an erosion ofphageal echo. Right: A vegetation removed by open heart surgery is shown.
CNS MSSA MRSA others culture negative
CNS
MSSAMRSA
Others
Culture
Negative
Fig. 2. Microbiology of the cardiac implantable electronic device infections
(n¼183).
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patients were receiving oral or intravenous antibiotics.4. Discussion
Cardiac implantable electronic devices became available in the
1970s. The use of CIEDs continues to grow in Japan. The rate of
device implantation is increasing with the aging of the general
population and the expanding indications. Voigt et al. [1] reported
that the rate of hospitalization for CIED infections have increased
faster than the rate of CIED implants. This disproportionate
increase is consistent with the ﬁndings of Cabell and colleagues [8]
who demonstrated accelerating rates of cardiac device infections
(including CIEDs, prosthetic valves, and ventricular assist devices)
among Medicare beneﬁciaries from 1990 to 1999 [5]. Voigt et al.
[1] suggested the reasons for such a disproportionate rise. First,
while the age has remained relatively constant, there has been an
increase in the prevalence of a coexistent morbidity in CIED reci-
pients. Uslan et al. [9] have shown that population-adjusted PM
implantation incidences have increased and that there has been an
age-independent rise in comorbidities in PM recipients. Thus, the
PM population may be becoming more susceptible to infections.
Second, Voigt et al. speculated that a widespread and potentially
indiscriminate CIED utilization for primary prevention of sudden
cardiac death and the treatment of heart failure might play a role,
primarily due to the disadvantaged health status and prevalent
comorbidities of such recipients. Particularly, given the adverse
impact of such comorbidities on the CRT response, a move to a
more judicious application of CIEDs, in general, may be warranted.
Interestingly a dramatic rise in CIED infections occurred beginning
in 2001 and 2002 [1], when the positive results of the primary
prevention deﬁbrillator trials [10,11] were accepted by the medical
community, followed by the adoption and increased rate of CRT
device implantations.
The data concerning device infections and lead extractions
from Japan are limited. Okamura et al. [2] reported their initial 40
cases. Ohmori et al. [3] reported a case of a thoracoscopy-guided
lead extraction with an excimer laser sheath and Okada et al. [4]
reported a case of a transjugular extraction using a snare techni-
que. Our current study consisted of 183 patients, the largest cohortin Japan, and, therefore, this study can clarify the status of device
infections and lead extractions in Japan.
Klug et al. [12] reported that device-related infections occurred
in 0.68% of patients within the ﬁrst year after the de novo
implantation or replacement. No data is available concerning the
prevalence of CIED infections in Japan, however at Kokura Mem-
orial Hospital, 1855 CIEDs were implanted between 2008 and 2012
(de novo implantations in 1,174 and replacements or upgrades in
681 patients). CIED infections occurred in 14 patients (0.75%). This
data suggests that the prevalence of CIED infections seems to be
similar in Japan.
As for the management of CIED infections, there have been no
randomized controlled trials. The recommendations for a com-
plete extraction of the device, route of administration, duration of
antimicrobial therapy, and the timing of the placement of a new
device are based on observational data and clinical experience.
Observations from several medical centers universally support the
complete removal of the device to cure the infection and reduce
morbidity and mortality [13–15]. The relapse rate when a com-
plete device removal is performed is 0–4.2%. On the contrary,
when a partial removal or antibiotics are chosen, the relapse rate
increases to 50–100% [9,13,16–19]. Removal of the generator
without a lead extraction should be avoided.
Of the 183 CIED infection patients, 27 (14.8%) had an early
infection (o3 months after the procedure), 45 (24.6%) had a late
infection (4–12 months after the device-related procedure), and
111 (60.7%) had a delayed infection (more than 12 months after
the procedure). Of interest, 60 (43.7%) patients presented with an
infection after an interval of more than 24 months after the
device-related procedure. These durations are longer than those
reported by Leckkerkerker et al. [20]. As previously mentioned,
almost half of the patients in this study had a previous surgical
intervention without a full removal of all hardware and one-fourth
of the patients underwent device implantation on the ipsilateral
side even though the infection was active in the PM pocket. This
might suggest a considerable number of patients were under-
treated in Japan and at a risk of recurring infections, endocarditis,
or fatal results.
Complete procedure success was achieved in 97.1% of the lead
extractions in our study while partial removal occurred in 2.0%,
and failure in 0.9%. Okamura et al. [2] reported the success rate of a
complete removal was 97.1%. These two results were almost
equally beneﬁcial with those of the LExICon study (complete
removal: 96.5%) [21]. The mean implant duration of the partially
removed leads was 1627101 months (longest 338 months). Roux
et al. [22] reported that a longer time from the implantation
independently predicted a procedural failure. In this patient group,
the mean implant duration of complete and partial removals was
86.1775.9 months and 162.07101.0 months, respectively
(po0.01).
In our study, culture results were positive for Staphylococcus
aureus in 37.1% of the patients, CNS in 30.1%, and other bacterial
species in 14.8%. Tarakji et al. [23] reported their pathogens of
CIED infections were CNS in 44.4% of the patients, Methicillin-
sensitive S. aureus (MSSA) in 20.1%, and Methicillin-resistant S.
aureus (MRSA) in 15.8%. Sohail et al. [17] reported CNS in 42%,
MSSA in 25%, and MRSA in 4%. Margey et al. [18] reported MSSA in
30.8%, CNS in 20.5%, and MRSA in 5.1%. Lekkerkerker et al. [20]
reported Staphylococcus aureus in 25% and CNS in 29%. Our data
and previously published data suggest that the Staphylococcus
species continues to represent the most common pathogen of CIED
infections, with 5–10% being methicillin resistant. The usefulness
of the prophylactic use of antibiotics at the time of a device
implantation was reported by de Oliveira et al. [24] Therefore
many institutions continue to use beta-lactam antimicrobial
agents at the time of implantation; however, this is not effective
M. Goya et al. / Journal of Arrhythmia 32 (2016) 308–312312against methicillin-resistant organisms. A single dose of vanco-
mycin before the implantation might be better than that of beta-
lactam antibiotics to prevent CIED infections in the selected
patients such as MRSA carrier.
Two patients in this patient group (1.1%) had relapses within
the ﬁrst year. One patient had a dual chamber ICD due to ven-
tricular tachycardia caused by a remote myocardial infarction. The
ICD was successfully extracted for a pocket infection due to coa-
gulase negative Staphylococcus. The pocket infection reappeared
after re-implantation of an ICD on the ipsilateral side at a previous
hospital. The pathogen of the second infection was Pseudomonas
aeruginosa; indicating that the second pocket infection might not
have been a recurrence of the initial pocket infection. The other
patient had allergic dermatitis on the body and a VDD PM was
implanted due to complete atrioventricular block. That patient
was referred to our hospital under a diagnosis of device-related
endocarditis. The device and all lead materials were completely
removed and the patient underwent successful re-implantation of
a device on the ipsilateral anterior chest after an intravenous
antibiotic prescription for three weeks. This patient, however, was
readmitted due to bacteremia after re-implantation of the device.
In our study, 8.1% of the patients no longer required device
implantation or had reasonable alternatives after their devices
were removed. Thus, the need for re-implantation in patients with
an infected device should be carefully evaluated.
4.1. Limitations
Our study does have a few limitations. Ninety percent of our
patients were initially treated by other institutions, and 47.5% had
previously failed surgical attempts without a full removal. This
study, therefore, has a potentially signiﬁcant referral bias. This
study consisted of the largest number of patients. However, this
report was a single center experience. Further investigation with a
larger patient group is required to clear up the present circum-
stances of CIED infections in Japan.5. Conclusions
The current clinical status of CIED infections seems to be
similar in Japan to that in foreign countries. The optimal treatment
of infected PM and implantable deﬁbrillator devices involves the
complete explantation of all hardware, followed by antibiotic
therapy. The excimer laser appeared to be safe and effective for
extracting chronically implanted leads in Japanese patients. Con-
servative treatment without explantation of all hardware is fre-
quently unsuccessful.Conﬂicts of interest
All authors declare no conﬂicts of interest related to this study.Acknowledgments
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